Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by degeneration of upper and lower motor neurons. To date, glycosylation patterns of glycoproteins in fluids of ALS patients have not been described. Moreover, the aberrant glycosylation related to the pathogenesis of other neurodegenerative diseases encouraged us to explore the glycome of ALS patient sera. We found high levels of sialylated glycans and low levels of core fucosylated glycans in serum-derived N-glycans of patients with ALS, compared to healthy volunteer sera. Based on these results, we analyzed the IgG Fc N(297)-glycans, as IgG are major serum glycoproteins affected by sialylation or core fucosylation and are found in the motor cortex of ALS patients. The analyses revealed a distinct glycan, A2BG2, in IgG derived from ALS patient sera (ALS-IgG). This glycan increases the affinity of IgG to CD16 on effector cells, consequently enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC). Therefore, we explore whether the Fc-N(297)-glycans of IgG may be involved in ALS disease. Immunostaining of brain and spinal cord tissues revealed over-expression of CD16 and co-localization of intact ALS-IgG with CD16 and in brain with activated microglia of G93A-SOD1 mice. Intact ALS-IgG enhanced effector cell activation and ADCC reaction in comparison to sugar-depleted or control IgG. ALS-IgG were localized in the synapse between brain microglia and neurons of G93A-SOD1 mice, manifesting a promising in vivo ADCC reaction. Therefore, glycans of ALS-IgG may serve as a biomarker for the disease and may be involved in neuronal damage.
Avram and Stella Goren-Goldstein Department of Biotechnology Engineering, Faculty of Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Meital
M
Edri-Brami
Benyamin
B
Rosental
Dana
D
Hayoun
Michael
M
Welt
Hila
H
Rosen
Itzhak
I
Wirguin
Beatrice
B
Nefussy
Vivian E
VE
Drory
Angel
A
Porgador
Rachel G
RG
Lichtenstein
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000690:Amyotrophic Lateral Sclerosis / Q000097:blood* / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity; D001692:Biological Transport / Q000276:immunology; D001921:Brain / Q000473:pathology; D016923:Cell Death / Q000276:immunology; D045744:Cell Line, Tumor; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology; D006023:Glycoproteins / Q000097:blood / Q000737:chemistry; D006801:Humans; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D017628:Microglia / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D009474:Neurons / Q000473:pathology*; D011134:Polysaccharides / Q000097:blood* / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism; D013116:Spinal Cord / Q000473:pathology; D013569:Synapses / Q000276:immunology / Q000378:metabolism; D013997:Time Factors
D006023:Glycoproteins; D011134:Polysaccharides; D017452:Receptors, IgG